|
業務類別
|
Biotechnology |
|
業務概覽
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designedto take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
| 公司地址
| 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 515-3185 |
| 傳真號碼
| +1 650 351-0353 |
| 公司網頁
| https://www.cytomx.com |
| 員工數量
| 69 |
| Dr. Sean A. McCarthy, D.Phil. |
Chief Executive Officer and Chairman of the Board |
美元 675.29K |
30/04/2026 |
| Mr. Yu-Waye Wayne Chu |
Senior Vice President and Chief Medical Officer |
-- |
30/04/2026 |
| Mr. Christopher W. Ogden |
Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
-- |
30/04/2026 |
| Dr. Marcia P. Belvin, PhD |
Senior Vice President and Chief Scientific Officer |
-- |
30/04/2026 |
| Ms. Rachael Lester |
Senior Vice President and Chief Business Officer |
美元 77.02K |
30/04/2026 |
|
|
| Mr. James R. Meyers |
Independent Director |
30/04/2026 |
| Dr. Elaine V. Jones, PhD |
Independent Director |
30/04/2026 |
| Ms. Halley E. Gilbert |
Independent Director |
30/04/2026 |
| Mr. Matthew P. Young |
Lead Independent Director |
30/04/2026 |
| Dr. Sean A. McCarthy, D.Phil. |
Chief Executive Officer and Chairman of the Board |
30/04/2026 |
| Dr. Mani Mohindru, PhD |
Independent Director |
30/04/2026 |
| Mr. Charles S. Fuchs |
Director |
27/07/2026 |
| Dr. Alan Ashworth, F.R.S.,PhD |
Independent Director |
30/04/2026 |
| Dr. Zhen Su, M.D. |
Independent Director |
30/04/2026 |
|
|
|
|
